Restoring regulation – IL-2 therapy in systemic lupus erythematosus
Authors:
- 23 June 2016
- journal article
- review article
- Published by Taylor & Francis in Expert Review of Clinical Immunology
- Vol. 12 (11) , 1153-1160
Abstract
The pathogenesis of systemic lupus erythematosus (SLE) involves an acquired deficiency of the cytokine IL-2, an essential growth and survival factor for regulatory T cells (Treg), which play an important role in the control of autoimmunity in SLE. In contrast to currently available therapies that broadly suppress the immune system, low-dose IL-2 therapy in SLE aims to compensate the pre-existing IL-2 deficiency and thus to restore a physiological state, where Treg can regain their ability to efficiently counteract autoimmunity. Areas covered: Here we summarize key findings that led to the development of this novel therapeutic concept and will highlight the key rationales for the clinical translation of low-dose IL-2 therapy in SLE. Expert commentary: The concept of low-dose IL-2 therapy in SLE has evolved from pathophysiological findings and thus can be considered a selective biological treatment strategy in SLE. Preliminary results from phase I/II studies are promising by proving selective Treg expansion and by providing first evidence for the clinical efficacy of low-dose IL-2 therapy in SLE.Keywords
This publication has 75 references indexed in Scilit:
- cAMP response element modulator α controls IL2 and IL17A expression during CD4 lineage commitment and subset distribution in lupusProceedings of the National Academy of Sciences, 2012
- Interleukin-2 Inhibits Germinal Center Formation by Limiting T Follicular Helper Cell DifferentiationImmunity, 2012
- cAMP-responsive Element Modulator (CREM)α Protein Signaling Mediates Epigenetic Remodeling of the Human Interleukin-2 GeneJournal of Biological Chemistry, 2011
- Transcriptional Activation of the cAMP-responsive Modulator Promoter in Human T Cells Is Regulated by Protein Phosphatase 2A-mediated Dephosphorylation of SP-1 and Reflects Disease Activity in Patients with Systemic Lupus ErythematosusJournal of Biological Chemistry, 2011
- IL-2 reverses established type 1 diabetes in NOD mice by a local effect on pancreatic regulatory T cellsJournal of Experimental Medicine, 2010
- Interleukin-2 Receptor Signaling: At the Interface between Tolerance and ImmunityImmunity, 2010
- Homeostatic imbalance of regulatory and effector T cells due to IL-2 deprivation amplifies murine lupusProceedings of the National Academy of Sciences, 2009
- Human T Regulatory Cell Therapy: Take a Billion or So and Call Me in the MorningImmunity, 2009
- In vivo expansion of T reg cells with IL-2–mAb complexes: induction of resistance to EAE and long-term acceptance of islet allografts without immunosuppressionJournal of Experimental Medicine, 2009
- Central Role of Defective Interleukin-2 Production in the Triggering of Islet Autoimmune DestructionImmunity, 2008